Literature DB >> 15956548

Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens.

Lan Wu1, Wing-Pui Kong, Gary J Nabel.   

Abstract

A variety of gene-based vaccination approaches have been used to enhance the immune response to viral pathogens. Among them, the ability to perform heterologous immunization by priming with DNA and boosting with replication-defective adenoviral (ADV) vectors encoding foreign antigens has proven particularly effective in eliciting enhanced cellular and humoral immunity compared to either agent alone. Because adenoviral vector immunization alone can elicit substantial cellular and humoral immune responses in a shorter period of time, we asked whether the immune response induced by the prime-boost immunization was different from adenoviral vaccines with respect to the potency and breadth of T-cell recognition. While DNA/ADV immunization stimulated the CD8 response, it was directed to the same epitopes in Gag and Env immunogens of human immunodeficiency virus as DNA or ADV alone. In contrast, the CD4 response to these immunogens diversified after DNA/ADV immunization compared to each vector alone. These findings suggest that the diversity of the CD4 immune response is increased by DNA/ADV prime-boost vaccination and that these components work synergistically to enhance T-cell epitope recognition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956548      PMCID: PMC1143709          DOI: 10.1128/JVI.79.13.8024-8031.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  DNA priming and recombinant pox virus boosters for an AIDS vaccine.

Authors:  H L Robinson; D C Montefiori; R P Johnson; M L Kalish; S L Lydy; H M McClure
Journal:  Dev Biol (Basel)       Date:  2000

2.  Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes.

Authors:  Sarah C Gilbert; Jörg Schneider; Carolyn M Hannan; Jiang Ting Hu; Magdalena Plebanski; Robert Sinden; Adrian V S Hill
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

3.  DNA vaccination with map1 gene followed by protein boost augments protection against challenge with Cowdria ruminantium, the agent of heartwater.

Authors:  Aceme Nyika; Anthony F Barbet; Michael J Burridge; Suman M Mahan
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

4.  Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys.

Authors:  D H Barouch; A Craiu; S Santra; M A Egan; J E Schmitz; M J Kuroda; T M Fu; J H Nam; L S Wyatt; M A Lifton; G R Krivulka; C E Nickerson; C I Lord; B Moss; M G Lewis; V M Hirsch; J W Shiver; N L Letvin
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen.

Authors:  T Matano; M Kano; H Nakamura; A Takeda; Y Nagai
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression.

Authors:  Y Huang; W P Kong ; G J Nabel
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

8.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

9.  DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins.

Authors:  P Pancholi; Q Liu; N Tricoche; P Zhang; M E Perkus; A M Prince
Journal:  J Infect Dis       Date:  2000-06-29       Impact factor: 5.226

10.  Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope.

Authors:  Zhi-yong Yang; Bimal K Chakrabarti; Ling Xu; Brent Welcher; Wing-pui Kong; Kwanyee Leung; Amos Panet; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

View more
  35 in total

1.  Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Authors:  Saravana K Kanagavelu; Victoria Snarsky; James M Termini; Sachin Gupta; Suzanne Barzee; Jacqueline A Wright; Wasif N Khan; Richard S Kornbluth; Geoffrey W Stone
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

2.  Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.

Authors:  Wing-pui Kong; Ling Xu; Konrad Stadler; Jeffrey B Ulmer; Sergio Abrignani; Rino Rappuoli; Gary J Nabel
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

3.  Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice.

Authors:  Shih-Wen Lin; Scott E Hensley; Nia Tatsis; Marcio O Lasaro; Hildegund C J Ertl
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

4.  Comparison of multiple vaccine vectors in a single heterologous prime-boost trial.

Authors:  Brice Barefoot; Natalie J Thornburg; Daniel H Barouch; Jae-Sung Yu; Christopher Sample; Robert E Johnston; Hua Xin Liao; Thomas B Kepler; Barton F Haynes; Elizabeth Ramsburg
Journal:  Vaccine       Date:  2008-09-20       Impact factor: 3.641

5.  Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines.

Authors:  Lukas Flatz; Rahul Roychoudhuri; Mitsuo Honda; Abdelali Filali-Mouhim; Jean-Philippe Goulet; Nadia Kettaf; Min Lin; Mario Roederer; Elias K Haddad; Rafick P Sékaly; Gary J Nabel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-21       Impact factor: 11.205

6.  DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults.

Authors:  Surender Khurana; Jian Wu; Milena Dimitrova; Lisa R King; Jody Manischewitz; Barney S Graham; Julie E Ledgerwood; Hana Golding
Journal:  J Infect Dis       Date:  2013-04-30       Impact factor: 5.226

7.  DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model.

Authors:  Anna D Kosinska; Lena Johrden; Ejuan Zhang; Melanie Fiedler; Anja Mayer; Oliver Wildner; Mengji Lu; Michael Roggendorf
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

8.  Prime-boost bacillus Calmette-Guérin vaccination with lentivirus-vectored and DNA-based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against Mycobacterium tuberculosis in mice.

Authors:  Ying Xu; Enzhuo Yang; Jianguang Wang; Rui Li; Guanghua Li; Guoyuan Liu; Na Song; Qi Huang; Cong Kong; Honghai Wang
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

9.  Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations.

Authors:  Amanda L Boehm; Jack Higgins; Alex Franzusoff; Jeffrey Schlom; James W Hodge
Journal:  Cancer Immunol Immunother       Date:  2009-09-16       Impact factor: 6.968

10.  Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response.

Authors:  P O Ilyinskii; A B Meriin; V L Gabai; O P Zhirnov; G Thoidis; A M Shneider
Journal:  Vaccine       Date:  2008-03-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.